Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice

Hepatology

Volumn 54, Issue 4, 2011, Pages 1398-1409

  Mueller, Kristina M ^a   Kornfeld, Jan Wilhelm ^b   Friedbichler, Katrin ^a   Blaas, Leander ^a   Egger, Gerda ^c   Esterbauer, Harald ^c   Hasselblatt, Peter ^d   Schlederer, Michaela ^a   Haindl, Susanne ^e   Wagner, Kay Uwe ^f   Engblom, David ^g   Haemmerle, Guenter ^h   Kratky, Dagmar ⁱ   Sexl, Veronika ^j   Kenner, Lukas ^a,c   Kozlov, Andrey V ^e   Terracciano, Luigi ^k   Zechner, Rudolf ^h   Schuetz, Guenther ^l   Casanova, Emilio ^a   Pospisilik, J Andrew ^m   Heim, Markus H ⁿ   Moriggl, Richard ^a   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF COLOGNE   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF FREIBURG   (Germany)

^e LUDWIG BOLTZMANN INSTITUTE FOR EXPERIMENTAL AND CLINICAL TRAUMATOLOGY   (Austria)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g LINKÖPING UNIVERSITY   (Sweden)

^h Institute of Molecular Biosciences   (Austria)

ⁱ MEDICAL UNIVERSITY OF GRAZ   (Austria)

^j UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^k UNIVERSITY HOSPITAL BASEL   (Switzerland)

^l GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^m MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

ⁿ UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; STAT5 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE COURSE; DNA DAMAGE; FATTY LIVER; HYPERCORTISOLISM; INSULIN RESISTANCE; LIPID METABOLISM; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; FATTY LIVER; GROWTH HORMONE; IMMUNOHISTOCHEMISTRY; LIPODYSTROPHY; LIVER NEOPLASMS; MALE; MICE; MICE, KNOCKOUT; RANDOM ALLOCATION; RECEPTORS, GLUCOCORTICOID; REFERENCE VALUES; RISK ASSESSMENT; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TISSUE CULTURE TECHNIQUES;

EID: 80053311826     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24509     Document Type: Article

References (45)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
2. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753-4761.
3. Cui Y, Hosui A, Sun R, Shen K, Gavrilova O, Chen W, et al. Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology 2007; 46: 504-513.
4. Fan Y, Menon RK, Cohen P, Hwang D, Clemens T, Digirolamo DJ, et al. Liver-specific deletion of the growth hormone receptor reveals essential role of GH signaling in hepatic lipid metabolism. J Biol Chem 2009; 284: 19937-19944.
5. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 1999; 274: 30028-30032.
6. Yang S, Lin HZ, Hwang J, Chacko VP, Diehl AM. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 2001; 61: 5016-5023.
7. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682-1698.
8. Bradbury MW, Berk PD. Lipid metabolism in hepatic steatosis. Clin Liver Dis 2004; 8: 639-671, xi.
9. Bradbury MW. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol 2006; 290: G194-G198.
10. Targher G, Bertolini L, Rodella S, Zoppini G, Zenari L, Falezza G. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006; 64: 337-341.
11. Lonardo A, Carani C, Carulli N, Loria P. "Endocrine NAFLD" a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol 2006; 44: 1196-1207.
12. Tronche F, Opherk C, Moriggl R, Kellendonk C, Reimann A, Schwake L, et al. Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev 2004; 18: 492-497.
13. Engblom D, Kornfeld JW, Schwake L, Tronche F, Reimann A, Beug H, et al. Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. Genes Dev 2007; 21: 1157-1162.
14. Johannsson G, Bengtsson BA. Growth hormone and the metabolic syndrome. J Endocrinol Invest 1999; 22: 41-46.
15. Hosui A, Kimura A, Yamaji D, Zhu BM, Na R, Hennighausen L. Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-beta> and STAT3 activation. J Exp Med 2009; 206: 819-831.
16. Sos BC, Harris C, Nordstrom SM, Tran JL, Balazs M, Caplazi P, et al. Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J Clin Invest 2011; 121: 1412-1423.
17. Barclay JL, Nelson CN, Ishikawa M, Murray LA, Kerr LM, McPhee TR, et al. GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology 2011; 152: 181-192.
18. Fain JN, Cheema P, Tichansky DS, Madan AK. Stimulation of human omental adipose tissue lipolysis by growth hormone plus dexamethasone. Mol Cell Endocrinol 2008; 295: 101-105.
19. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832.
20. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208.
21. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004; 39: 909-914.
22. Ichikawa T, Hamasaki K, Ishikawa H, Ejima E, Eguchi K, Nakao K. Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut 2003; 52: 914.
23. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58: 1538-1544.
24. Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci U S A 1998; 95: 4333-4337.
25. Shipley JM, Waxman DJ. Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b. Toxicol Appl Pharmacol 2004; 199: 275-284.
26. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000; 6: 77-86.
27. Muraoka T, Aoki K, Iwasaki T, Shinoda K, Nakamura A, Aburatani H, et al. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 2011; 60: 617-628.
28. Chen J, Sadowski HB, Kohanski RA, Wang LH. Stat5 is a physiological substrate of the insulin receptor. Proc Natl Acad Sci U S A 1997; 94: 2295-2300.
29. Storz P, Doppler H, Pfizenmaier K, Muller G. Insulin selectively activates STAT5b, but not STAT5a, via a JAK2-independent signalling pathway in Kym-1 rhabdomyosarcoma cells. FEBS Lett 1999; 464: 159-163.
30. Sawka-Verhelle D, Tartare-Deckert S, Decaux JF, Girard J, Van Obberghen E. Stat 5B, activated by insulin in a Jak-independent fashion, plays a role in glucokinase gene transcription. Endocrinology 2000; 141: 1977-1988.
31. Cole TJ, Harris HJ, Hoong I, Solomon N, Smith R, Krozowski Z, Fullerton MJ. The glucocorticoid receptor is essential for maintaining basal and dexamethasone-induced repression of the murine corticosteroid-binding globulin gene. Mol Cell Endocrinol 1999; 154: 29-36.
32. Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC. Intracellular regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11beta-HSD-1-deficient mice. Endocrinology 2001; 142: 114-120.
33. Viau V, Meaney MJ. Testosterone-dependent variations in plasma and intrapituitary corticosteroid binding globulin and stress hypothalamic-pituitary-adrenal activity in the male rat. J Endocrinol 2004; 181: 223-231.
34. Ren T, He J, Jiang H, Zu L, Pu S, Guo X, Xu G. Metformin reduces lipolysis in primary rat adipocytes stimulated by tumor necrosis factor-alpha or isoproterenol. J Mol Endocrinol 2006; 37: 175-183.
35. Watt MJ, Steinberg GR. Regulation and function of triacylglycerol lipases in cellular metabolism. Biochem J 2008; 414: 313-325.
36. Schweiger M, Schreiber R, Haemmerle G, Lass A, Fledelius C, Jacobsen P, et al. Adipose triglyceride lipase and hormone-sensitive lipase are the major enzymes in adipose tissue triacylglycerol catabolism. J Biol Chem 2006; 281: 40236-40241.
37. Blaas L, Kornfeld JW, Schramek D, Musteanu M, Zollner G, Gumhold J, et al. Disruption of the growth hormone-signal transducer and activator of transcription 5-insulin-like growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology 2010; 51: 1319-1326.
38. Yu JH, Zhu BM, Wickre M, Riedlinger G, Chen W, Hosui A, et al. The transcription factors signal transducer and activator of transcription 5A (STAT5A) and STAT5B negatively regulate cell proliferation through the activation of cyclin-dependent kinase inhibitor 2b (Cdkn2b) and Cdkn1a expression. Hepatology 2010; 52: 1808-1818.
39. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004; 113: 1774-1783.
40. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11: 119-132.
41. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-859.
42. Zhou YC, Waxman DJ. STAT5b down-regulates peroxisome proliferator-activated receptor alpha transcription by inhibition of ligand-independent activation function region-1 trans-activation domain. J Biol Chem 1999; 274: 29874-29882.
43. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-549.
44. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006; 130: 1117-1128.
45. Elias JA, Lentz V. IL-1 and tumor necrosis factor synergistically stimulate fibroblast IL-6 production and stabilize IL-6 messenger RNA. J Immunol 1990; 145: 161-166.